FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Vashington, | $D \subset$ | 20549 | |
|--------------|-------------|-------|--|
| vasilligion, | D.C. | 20049 | |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | | | |
| Estimated average burden | | | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Wallace Richard John | | | 2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN] | | | | | | (Ch | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | | | | | |
|--|--|--|--|--|---|--|---|----------|-----------------------------------|---|---|---|--------------------|--|--|-----------|--|--|
| (Last) | , | * | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 06/14/2023 | | | | | | Officer below) | (give title | | Other (s below) | pecify | | | |
| C/O IMMUNOGEN, INC. 830 WINTER STREET | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | Line | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | | | |
| (Street) | AM M | A | 02451 | | | | | | | | | Form filed by More than One Reporting Person | | | | | | |
| (City) | (Si | tate) | (Zip) | | □ c | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Inst | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transar Date (Month/Date | | | Execution Date, | | Code (Instr. 5) | | | Benefici | es Fo ally (D Following (I) | Form | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | | | | | |
| | | | | | | Code V Amount (A) or (D) | | | | | Price | Transac (Instr. 3 | tion(s) | | | Instr. 4) | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Da if any (Month/Day/\) | | 4. 5. Number of Ecode (Instr. Derivative (| | 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4) | | | of s ig e Security | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | C | ode ' | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Restricted Stock Unit | \$0 ⁽¹⁾ | 06/14/2023 | | | A | | 13,090 | | (2) | (2) | Common Stock | 13,090 | \$0 ⁽¹⁾ | 13,090 | | D | | |
| Stock Option (right to buy) | \$17.72 ⁽³⁾ | 06/14/2023 | | | A | | 19,597 | | (4) | 06/14/2033 | Common Stock | 19,597 | \$0 | 19,597 | 7 | D | | |

Explanation of Responses:

- 1. The restricted stock units ("RSUs") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- 2. The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date.
- 3. The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended.
- 4. The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date.

/s/ Renee Lentini, Attorney-in-06/16/2023 Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.